Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial

Area of Science:

• Neurology
• Pharmacology
• Clinical Trials

Background:

• Parkinson disease (PD) management often involves dopaminergic agonists, but adverse events (AEs) linked to D2/D3 receptor activation can limit efficacy.
• Tavapadon, a selective D1/D5 agonist, presents a potential therapeutic strategy to improve PD motor symptoms while mitigating AEs associated with D2/D3 receptor stimulation.

Purpose of the Study:

• To assess the efficacy, safety, and tolerability of tavapadon in adults diagnosed with early-stage Parkinson disease.
• To evaluate tavapadon's impact on motor symptoms and patient-reported outcomes compared to placebo.

Main Methods:

• The TEMPO-1 trial was a Phase 3, double-blind, placebo-controlled study involving 529 adults with early PD.
• Participants received fixed daily doses of tavapadon (5 mg or 15 mg) or placebo for 27 weeks, with efficacy measured by changes in the MDS-UPDRS scores.

Main Results:

• Tavapadon treatment (5 mg and 15 mg) resulted in statistically significant improvements in the combined MDS-UPDRS parts II and III scores compared to placebo.
• The drug was well-tolerated, with most AEs being mild to moderate; common side effects included nausea, headache, and dizziness.

Conclusions:

• Tavapadon demonstrated significant efficacy in improving motor function for individuals with early Parkinson disease.
• The favorable safety profile and tolerability suggest tavapadon is a viable and promising therapeutic option for managing early PD.